期刊文献+

Advances in hydrogel materials applied to pancreatic-related diseases

原文传递
导出
摘要 The pancreas is a glandular organ that maintains internal homeostasis through its endocrine and exocrine functions.These functions are vital for overall well-being.However,environmental and lifestyle changes have led to an increasing incidence of pancreatic diseases,including pancreatic cancer,pancreatitis,and pancreatic neuroendocrine tumors.These conditions profoundly impact the health and quality of life of affected individuals.The existing diagnostic and treatment approaches for pancreatic diseases exhibit limitations and shortcomings,necessitating exploring novel strategies.In recent years,advancements in medicine and bioengineering have fostered multidisciplinary and interdisciplinary innovations,introducing fresh avenues for diagnosing and treating pancreatic diseases.Hydrogels,emerging as a biomaterial,represent highly hydrated cross-linked hydrophilic polymer networks.Their exceptional biodegradability and biocompatibility have rendered them instrumental in various medical applications.Hydrogels,with their macromolecular porous structures,are efficient carriers for drug delivery and controlled release.Hydrogel materials have garnered substantial attention for their unique properties and diverse applications in the context of pancreatic diseases.This article aims to provide an overview of the current limitations in diagnosing and treating pancreatic diseases while highlighting the latest trends and advancements in developing hydrogel carrier materials tailored for these conditions,primarily focusing on strategies for pancreatitis,pancreatic cancer,and pancreatic neuroendocrine tumors.The article endeavors to give researchers and clinicians a comprehensive grasp of this field,offering valuable insights into prospective research directions and emerging trends.
出处 《Journal of Pancreatology》 2024年第3期222-232,共11页 胰腺病学杂志(英文)
基金 The study was supported by Medical Minimally Invasive Center Program of Fujian Province and National Key Clinical Specialty Discipline Construction Program,China(No.2021-76) Natural Science Foundation of Fujian Province(2023J01097).
  • 相关文献

参考文献6

二级参考文献140

  • 1Andrew D. Rhim,Paul E. Oberstein,Dafydd H. Thomas,Emily T. Mirek,Carmine F. Palermo,Stephen A. Sastra,Erin N. Dekleva,Tyler Saunders,Claudia P. Becerra,Ian W. Tattersall,C. Benedikt Westphalen,Jan Kitajewski,Maite G. Fernandez-Barrena,Martin E. Fernandez-Zapico,Christine Iacobuzio-Donahue,Kenneth P. Olive,Ben Z. Stanger.Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma[J]. Cancer Cell . 2014 被引量:5
  • 2Cochrane Dawn R,Spoelstra Nicole S,Howe Erin N,Nordeen Steven K,Richer Jennifer K.MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Molecular Cancer . 2009 被引量:3
  • 3Hwang Jin-Hyeok,Voortman Johannes,Giovannetti Elisa,Steinberg Seth M,Leon Leticia G,Kim Yong-Tae,Funel Niccola,Park Joo Kyung,Kim Min A,Kang Gyeong Hoon,Kim Sun-Whe,Del Chiaro Marco,Peters Godefridus J,Giaccone Giuseppe.Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PloS one . 2010 被引量:2
  • 4J.B. Kjersem,T. Ikdahl,O.C. Lingjaerde,T. Guren,K.M. Tveit,E.H. Kure.Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment[J]. Molecular Oncology . 2014 (1) 被引量:4
  • 5Gregory L. Beatty,Drew A. Torigian,E. Gabriela Chiorean,Babak Saboury,Alex Brothers,Abass Alavi,Andrea B. Troxel,Weijing Sun,Ursina R. Teitelbaum,Robert H. Vonderheide,Peter J. O’Dwyer.A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma[J].Clinical Cancer Research.2013(22) 被引量:6
  • 6Philippe Rougier,Hanno Riess,Robert Manges,Petr Karasek,Yves Humblet,Carlo Barone,Armando Santoro,Sylvie Assadourian,Laurence Hatteville,Philip A. Philip.Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer[J].European Journal of Cancer.2013(12) 被引量:4
  • 7Mads H. Rasmussen,Niels F. Jensen,Line S. Tarpgaard,Camilla Qvortrup,Maria U. R?mer,Jan Stenvang,Tine P. Hansen,Lise L. Christensen,Jan Lindebjerg,Flemming Hansen,Benny V. Jensen,Torben F. Hansen,Per Pfeiffer,Nils Brünner,Torben F. ?rntoft,Claus L. Andersen.High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer[J].Molecular Oncology.2013(3) 被引量:2
  • 8Hedy L Kindler,Tatsuya Ioka,Dirk J Richel,Jaafar Bennouna,Richard Létourneau,Takuji Okusaka,Akihiro Funakoshi,Junji Furuse,Young Suk Park,Shinichi Ohkawa,Gregory M Springett,Harpreet S Wasan,Peter C Trask,Paul Bycott,Alejandro D Ricart,Sinil Kim,Eric Van Cutsem.Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study[J].Lancet Oncology.2011(3) 被引量:4
  • 9Chenwei Li,Jing–Jiang Wu,Mark Hynes,Joseph Dosch,Bedabrata Sarkar,Theodore H. Welling,Marina Pasca di Magliano,Diane M. Simeone.c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target[J].Gastroenterology.2011(6) 被引量:3
  • 10Ami N. Shah,Justin M. Summy,Jing Zhang,Serk In Park,Nila U. Parikh,Gary E. Gallick.Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells[J].Annals of Surgical Oncology.2007(12) 被引量:2

共引文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部